GLPGF — Lakefront Biotherapeutics NV
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1421876 ·
Belgium
Last close
$35.15
Market Cap
$2.30B
52W High
$35.15
52W Low
$26.24
ADV30
3
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 7,578,000 | 3,901,000 | -41,172,000 | -2,671,000 | 3,294,568,000 | 94,655,000 | 61,806,000 |
| Jun 2026 | 12,110,000 | 2,965,000 | -43,511,000 | 2,109,000 | 3,351,188,000 | 135,952,000 | 87,558,000 |
| Mar 2026 | 6,481,000 | 1,682,000 | -63,703,000 | 14,492,000 | 3,372,429,000 | 66,805,000 | 119,060,000 |
| Dec 2025 | 900,822,000 | 900,367,000 | 758,798,000 | 782,146,000 | 3,406,518,000 | 87,868,000 | 170,650,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-226,909,000
Investing CF
$292,276,000
Financing CF
$-6,110,000
CapEx
$-4,606,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.11
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$233,958,000
Inventory
$8,544,000
Receivables
$56,296,000
ST Investments
$2,103,597,000
EBIT TTM
$579,011,000
Pretax Income TTM
$577,632,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$990,574,016
EBITDA
$568,918,016
Free Cash Flow
$138,206,256
Enterprise Value
$-510,395,424
Total Cash
$2,239,548,928
Total Debt
$6,362,000
Shares Out
65,484,670
Trailing EPS
$10.49
Book Value
$57.73
ROE
20.1%
ROA
9.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,112,248,000 | 501,391,000 | 320,884,000 | 3,406,518,000 | 170,650,000 | 3,235,868,000 | -257,456,000 |
| Dec 2024 | 275,649,000 | -188,338,000 | 74,082,000 | 4,135,719,000 | 1,238,780,000 | 2,896,939,000 | -320,026,000 |
| Dec 2023 | 239,724,000 | -88,263,000 | 211,697,000 | 4,357,396,000 | 1,561,830,000 | 2,795,566,000 | -405,970,000 |
| Dec 2022 | 241,249,000 | -131,057,000 | -217,991,000 | 4,734,351,000 | 2,208,325,000 | 2,526,026,000 | -500,544,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PBH | Prestige Consumer Healthcare Inc. | $2.29B | $48.22 | — |
| NAMS | NewAmsterdam Pharma Co N.V. | $2.33B | $19.39 | — |
| PHVS | Pharvaris N.V. | $2.27B | $32.28 | — |
| LKFT | Lakefront Biotherapeutics NV | $2.25B | $34.39 | — |
| RCUS | Arcus Biosciences, Inc. | $2.36B | $16.39 | — |
News headlines (Yahoo Finance, 1h cache)
Lakefront Creates New Subscription Right Plan
2026-11-18 21:01 · Yahoo
Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program
2026-11-16 06:30 · Yahoo
Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update
2026-11-11 21:01 · Yahoo
Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London
2026-11-10 21:01 · Yahoo
Is Lakefront Biotherapeutics (ENXTAM:LKFT) Cheap Given Its Earnings Today?
2026-11-10 14:12 · Yahoo
Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?
2026-11-06 13:55 · Yahoo
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
2026-11-04 14:01 · Yahoo
Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors
2026-11-02 21:01 · Yahoo
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?
2026-10-21 15:00 · Yahoo
Lakefront Biotherapeutics (ENXTAM:LKFT) Stock Looks Undervalued Despite A 40% Five Year Fall
2026-10-21 05:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.